Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 3 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 3 5 W ELECTROLYTES.
AMINOSYN-HF 8% vs TRAVASOL 3.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids (3.5% crystalline amino acids) and electrolytes for protein synthesis and maintenance of electrolyte balance in patients unable to meet nutritional needs enterally. The amino acids serve as substrates for protein synthesis, while electrolytes support cellular function and acid-base balance.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution